Key advances in the clinical approach to ANCA-associated vasculitis (Q38224803)

31 August 2017

Key advances in the clinical approach to ANCA-associated vasculitis (English)

1 reference

31 August 2017

1

Cees G M Kallenberg

1 reference

PubMed ID

24980139

31 August 2017

language of work or name

English

0 references

publication date

1 July 2014

1 reference

Nature Reviews Rheumatology

31 August 2017

1 reference

31 August 2017

10

1 reference

31 August 2017

484-493

1 reference

31 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2014.104

31 August 2017

0 references

cites work

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Evaluation of a new algorithm in classification of systemic vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Re-evaluation of 129 patients with systemic necrotizing vasculitides by using classification algorithm according to consensus methodology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Increased sensitivity of the European medicines agency algorithm for classification of childhood granulomatosis with polyangiitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Classification of vasculitis: EMA classification using CHCC 2012 definitions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Genetically distinct subsets within ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

ANCA-negative pauci-immune crescentic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Anti-neutrophil cytoplasmic autoantibody pathogenicity revisited: pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Treatment of ANCA-associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Long-term patient survival in ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

The characterisation and determinants of quality of life in ANCA associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

EULAR recommendations for the management of primary small and medium vessel vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

L52. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Antineutrophil cytoplasm antibody-associated vasculitis: recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Maintenance of clinical remission in ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Antiproteinase 3- and antimyeloperoxidase-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Efficacy of remission-induction regimens for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Rheumatic manifestations of cocaine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Complement in ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

C5a receptor (CD88) blockade protects against MPO-ANCA GN

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Wegener Granulomatosis: An Analysis of 158 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Azathioprine or methotrexate maintenance for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

21 January 2018

Biomarkers in vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

A CD8+ T cell transcription signature predicts prognosis in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Complications of long-term therapy for ANCA-associated systemic vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

L42. Morbidity in patients with ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Venous thromboembolism in ANCA-associated vasculitis--incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

SLE and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Malignancy is increased in ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Etanercept plus standard therapy for Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Antineutrophil cytoplasmic autoantibody-negative Pauci-immune crescentic glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Churg-Strauss syndrome: just one disease entity?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Modification and validation of the Birmingham Vasculitis Activity Score (version 3)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. A prospective study in 117 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Successful Treatment of ANCA-Negative Wegener's Granulomatosis with Rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Cancer preceding Wegener's granulomatosis: a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.104

Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease

31 March 2020

1 reference

12 December 2020

Progressive multifocal encephalopathy after cyclophosphamide in granulomatosis with polyangiitis (Wegener) patients: case report and review of literature

1 reference

12 December 2020

Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

1 reference

12 December 2020

Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement

1 reference

12 December 2020

ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS).

1 reference

12 December 2020

Intra- and inter-rater reliability of endonasal activity estimation in granulomatosis with polyangiitis (Wegener´s).

1 reference

12 December 2020

Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2014.104

1 reference

PubMed ID

24980139

Dimensions Publication ID

31 August 2017

0 references

1 reference

PubMed ID

24980139